These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32986633)

  • 21. Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease.
    Giuliano C; Siani F; Mus L; Ghezzi C; Cerri S; Pacchetti B; Bigogno C; Blandini F
    Nutrition; 2020 Jan; 69():110494. PubMed ID: 31586482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
    Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
    J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.
    Silva-Adaya D; Pérez-De La Cruz V; Villeda-Hernández J; Carrillo-Mora P; González-Herrera IG; García E; Colín-Barenque L; Pedraza-Chaverrí J; Santamaría A
    Neurotoxicol Teratol; 2011; 33(2):303-12. PubMed ID: 20933078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
    Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
    Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
    Costa G; Abin-Carriquiry JA; Dajas F
    Brain Res; 2001 Jan; 888(2):336-342. PubMed ID: 11150495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson's Disease.
    Manouchehrabadi M; Farhadi M; Azizi Z; Torkaman-Boutorabi A
    Neurotox Res; 2020 Jan; 37(1):156-170. PubMed ID: 31364033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is nicotine protective against Parkinson's disease? An experimental analysis.
    García-Montes JR; Boronat-García A; López-Colomé AM; Bargas J; Guerra-Crespo M; Drucker-Colín R
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):897-906. PubMed ID: 23131151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
    Abuirmeileh A; Lever R; Kingsbury AE; Lees AJ; Locke IC; Knight RA; Chowdrey HS; Biggs CS; Whitton PS
    Eur J Neurosci; 2007 Jul; 26(2):417-23. PubMed ID: 17650114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease.
    Gonzalo-Gobernado R; Calatrava-Ferreras L; Reimers D; Herranz AS; Rodríguez-Serrano M; Miranda C; Jiménez-Escrig A; Díaz-Gil JJ; Bazán E
    PLoS One; 2013; 8(7):e67771. PubMed ID: 23861803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease.
    Yeni Y; Genc S; Ertugrul MS; Nadaroglu H; Gezer A; Mendil AS; Hacımuftuoglu A
    Sci Rep; 2024 Aug; 14(1):19077. PubMed ID: 39154054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
    Kääriäinen TM; Piltonen M; Ossola B; Kekki H; Lehtonen S; Nenonen T; Lecklin A; Raasmaja A; Männistö PT
    Brain Res; 2008 Apr; 1203():149-59. PubMed ID: 18329008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
    Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
    Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study.
    Liu CT; Kao LT; Shih JH; Chien WC; Chiu CH; Ma KH; Huang YS; Cheng CY; Shiue CY; Li IH
    Eur J Pharmacol; 2019 Nov; 862():172639. PubMed ID: 31491406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Administration of Endogenous Amines TIQ and 1MeTIQ Protects Against a 6-OHDA-Induced Essential Fall of Dopamine Release in the Rat Striatum: In Vivo Microdialysis Study.
    Wąsik A; Romańska I; Zelek-Molik A; Antkiewicz-Michaluk L
    Neurotox Res; 2018 Apr; 33(3):523-531. PubMed ID: 29076060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.